核心试验
2010年8月25日
内部消息——癌症候选药物概述
当地合同研究组织（CRO）Novotech进行的一组三项I期试验正在大力推广OncoMed生产的抗癌人源化单克隆抗体OMP-21M18。三项试验旨在确定OMR-21M18与几种不同癌症的标准治疗化疗方案相结合时的安全性、疗效、药代动力学特征和最大耐受剂量。
作者：Simone du Toit
全球职业机会
Featured
Thought Leadership
文章
Featured media on Novotech’s leadership and impact.
博客
Expert insights and real-world perspectives.
白皮书
In-depth perspectives on forces shaping clinical research.
疾病报告
Tracking science and trends across therapeutic areas.
网络研讨会
Hear from experts shaping clinical development.
Podcasts
Conversations with leaders shaping drug development.
Featured
关于我们
关于我们
A global CRO and scientific partner advancing drug development.
社会影响
Our impact extends beyond trials, shaping healthier futures worldwide.
公司文化
A collaborative, science-driven approach.
奖项和荣誉
Recognized for excellence across the industry.
领导团队
Decades of clinical and scientific leadership.
招贤纳士
成长平台
A global clinical research leader with an award-winning culture.
活力职场
A culture that empowers growth, innovation, and impact.
当前职位
Explore career opportunities at Novotech.
员工福利与表彰制度
Benefits and recognition that support your success.
携手同行
Experts collaborating to advance clinical research.
Career Growth and Development
A commitment to your growth and development.
2019/5/17